SUBSCRIBE
SUBSCRIBE

Salarius Pharmaceuticals

NEWS
Drug Development
Salarius Stock Plunges 27% After Death in Sarcoma Trial
Salarius Pharmaceuticals voluntarily paused enrollment of its Phase I/II trial of seclidemstat for Ewing sarcoma and FET-rearranged sarcomas after a patient’s death.
October 18, 2022
 · 
2 min read
 · 
Mark Terry
Biotech Beach
BIO Returns to San Diego with Innovation and Partnering on the Menu
The annual BIO convention has returned, bringing thousands of life sciences companies worldwide to the annual networking event that could spark collaborations and deals.
June 14, 2022
 · 
3 min read
 · 
Alex Keown
IN THE PRESS
Business
Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
March 22, 2024
 · 
13 min read
Lone Star Bio
Salarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses
February 22, 2024
 · 
9 min read
Lone Star Bio
Salarius Pharmaceuticals Issued U.S. Patent for Next-Generation Targeted Protein Degraders
January 16, 2024
 · 
5 min read
Drug Development
Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals’ Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment
January 3, 2024
 · 
8 min read
Policy
Salarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program
November 7, 2023
 · 
7 min read
Business
Salarius Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides a Business Update
August 10, 2023
 · 
13 min read
Lone Star Bio
Salarius Pharmaceuticals Announces Plans to Explore Strategic Alternatives and Implement Measures to Extend its Resources
August 8, 2023
 · 
9 min read
Drug Development
Salarius Pharmaceuticals Receives FDA Clearance of SP-3164 Investigational New Drug Application to Begin a Phase 1 Clinical Trial in Relapsed/Refractory Non-Hodgkin Lymphoma Patients
July 11, 2023
 · 
7 min read
Drug Development
Salarius Pharmaceuticals Presents SP-3164 Targeted Protein Degrader Preclinical Data at the European Hematology Association 2023 Hybrid Congress
June 12, 2023
 · 
6 min read
Lone Star Bio
Salarius Pharmaceuticals Announces Closing of $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules
May 16, 2023
 · 
6 min read
Load More
JOBS